Novavax, Inc. (NVAX) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
NVAX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, Novavax, Inc. (NVAX) trades at a price-to-earnings ratio of 3.7x, with a stock price of $9.36 and trailing twelve-month earnings per share of $-0.54.
The current P/E is 14% above its 5-year average of 3.2x. Over the past five years, NVAX's P/E has ranged from a low of 2.4x to a high of 4.9x, placing the current valuation at the 75th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, NVAX trades at a 83% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, NVAX trades at a notable discount to the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NVAX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
NVAX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $151B | 19.5 | - | -4% | |
| $106B | 18.4 | - | -7% | |
| $102B | 6.7Lowest | 0.47Best | +348% | |
| $2B | 77.5 | - | +503%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
NVAX Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $6.72 | $2.39 | 2.8x | -13% |
| FY2025 Q3 | $8.67 | $1.77 | 4.9x | +52% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $6.30 | $2.26 | 2.8x | -14% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $6.41 | $2.65 | 2.4x | -25% |
Average P/E for displayed period: 3.2x
See NVAX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NVAX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NVAX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNVAX — Frequently Asked Questions
Quick answers to the most common questions about buying NVAX stock.
Is NVAX stock overvalued or undervalued?
NVAX trades at 3.7x P/E, near its 5-year average of 3.2x. The 75th percentile ranking places valuation within normal historical bounds.
How does NVAX's valuation compare to peers?
Novavax, Inc. P/E of 3.7x compares to sector median of 22.1x. The discount suggests lower growth expectations or higher risk.
What is NVAX's PEG ratio?
NVAX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.